| LMIC-15. OUTCOMES OF PEDIATRIC MEDULLOBLASTOMA IN LOW-AND MIDDLE-INCOME COUNTRIES: A REPORT OF 330 PATIENTS FROM 8 COUNTRIES R Diaz-Coronado, E Hernandez-Broncano, T Negreiros-Chinchihuara, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children CS Escherich, W Chen, Y Li, W Yang, R Nishii, Z Li, EA Raetz, M Devidas, ... Blood 143 (22), 2270-2283, 2024 | 1 | 2024 |
| MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231 RJ Hayashi, ML Hermiston, BL Wood, DT Teachey, M Devidas, Z Chen, ... Blood 143 (20), 2053-2058, 2024 | 1 | 2024 |
| Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study S Alexander, JA Kairalla, S Gupta, E Hibbitts, H Weisman, D Anghelescu, ... Journal of Clinical Oncology, JCO. 23.01989, 2024 | 1 | 2024 |
| Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report NJ DelRocco, ML Loh, MJ Borowitz, S Gupta, KR Rabin, ... Leukemia 38 (4), 720-728, 2024 | 1 | 2024 |
| Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma DC Moreira, I Qaddoumi, S Spiller, TW Bouldin, A Davidson, N Saba-Silva, ... Neuro-oncology, noae048, 2024 | 1 | 2024 |
| Connecting Clinical Capacity and Intervention Sustainability in Resource-Variable Pediatric Oncology Centers in Latin America V McKay, Y Chen, K Prewitt, S Malone, M Puerto-Torres, C Acuña-Aguirre, ... Global implementation research and applications 4 (1), 102-115, 2024 | | 2024 |
| Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232 LA Mattano Jr, M Devidas, ML Loh, EA Raetz, Z Chen, NJ Winick, ... Leukemia 38 (2), 258-265, 2024 | 3 | 2024 |
| Treatment of high‐risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes S Luna‐Fineman, M Castellanos, ML Metzger, LF Baez, ... Pediatric Blood & Cancer 71 (2), e30792, 2024 | 1 | 2024 |
| Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group KR Rabin, M Devidas, Z Chen, L Ji, J Kairalla, JK Hitzler, JJ Yang, ... Journal of Clinical Oncology 42 (2), 218-227, 2024 | 4 | 2024 |
| 776: MORTALITY AMONG PEDIATRIC HEMATOLOGY-ONCOLOGY PATIENTS WITH CLINICAL DETERIORATION IN LATIN AMERICA A Agulnik, MR Murguia, H Muniz-Talavera, LTD Pham, AC Aguirre, ... Critical Care Medicine 52 (1), S360, 2024 | | 2024 |
| Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study BL Wood, M Devidas, RJ Summers, Z Chen, B Asselin, KR Rabin, ... Blood 142 (24), 2069-2078, 2023 | 15 | 2023 |
| Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's … SI Colace, M Devidas, ZB Chen, RJ Hayashi, BL Wood, N Esiashvili, ... Blood 142, 517, 2023 | 2 | 2023 |
| Heritable Variation in Lymphocyte-Related Traits and Risk of Down Syndrome Acute Lymphoblastic Leukemia: A Mendelian Randomization Study Y Li, MA Richard, L Kachuri, Y Yu, CJR Hsu, TC Rosser, EJ Leslie, ... Blood 142, 4198, 2023 | | 2023 |
| Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL) N Roy, ZJ Mao, C Xu, DT Teachey, ZB Chen, M Devidas, X Chen, ... Blood 142, 2976, 2023 | | 2023 |
| Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL … WL Salzer, MJ Burke, M Devidas, ZB Chen, MJ Borowitz, AJ Carroll, ... Blood 142, 961, 2023 | 1 | 2023 |
| Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology … V Rodriguez, M Devidas, ZB Chen, AJ Carroll, NA Heerema, MJ Borowitz, ... Blood 142, 824, 2023 | 1 | 2023 |
| Evaluating Blinatumomab Treatment Adoption in Varied Resource Settings Using the RE-AIM Framework C Duffy, Z Fadoo, N Ghara, V Santana, H Inaba, S Jeha, Y Chen, L Pham, ... Blood 142, 3713, 2023 | | 2023 |
| Sustainability determinants of an intervention to identify clinical deterioration and improve childhood cancer survival in Latin American hospitals: the INSPIRE study protocol V McKay, B Carothers, D Graetz, S Malone, M Puerto-Torres, K Prewitt, ... Implementation Science Communications 4 (1), 141, 2023 | | 2023 |
| Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials EA Raetz, P Rebora, V Conter, M Schrappe, M Devidas, G Escherich, ... Journal of Clinical Oncology 41 (32), 5025-5034, 2023 | 2 | 2023 |